Immunome
IMNM
113 hedge funds and large institutions have $578M invested in Immunome in 2024 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
36% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $882K
13.67% more ownership
Funds ownership: 66% → 79.67% (+14%)
9% more funds holding
Funds holding: 104 → 113 (+9)
36% less capital invested
Capital invested by funds: $907M → $578M (-$329M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$45.8M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$37M |
| 3 |
State Street
Boston,
Massachusetts
|
+$33.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$25.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.7M |
| 3 |
Millennium Management
New York
|
-$11.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$9.37M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$6.18M |
IMNM Hedge Fund Activity: Q2 2024 in Review
113 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2024, worth a combined $578M — down 36% from $907M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IMNM positions and 28 closed out — a net gain of 11 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $45.8M. The largest seller was Point72 Asset Management, cutting an estimated $19.7M.
- 113 institutional investors held Immunome (IMNM) as of Q2 2024, up from 104 in Q1 2024.
- Funds reported $578M of Immunome stock for Q2 2024, down 36% quarter-over-quarter.
- 39 funds opened new Immunome positions in Q2 2024 and 28 closed out, a net change of +11 holders.
- The largest Immunome buyer in Q2 2024 was BlackRock, an estimated $45.8M added.
- The largest Immunome seller in Q2 2024 was Point72 Asset Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q2 2024.